Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | PPARG | P37231 | 8/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570631 | 0.88 | MAPT (0.67) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL9570559 | 0.85 | MAPT (0.83) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL27576709 | 0.83 | PPARG (0.65) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL9570641 | 0.82 | MAPT (0.60) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL10483600 | 0.81 | MAPT (0.58) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL290413 | 0.80 | MAPT (0.75) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL9372807 | 0.79 | PPARG (0.60) | MAPTPPARGALDH1A1NPSR1MAOA | |
| Glitazone SCHEMBL623021 | 0.79 | MAPT (0.73) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL4852588 | 0.79 | MAPT (0.73) | MAPTPPARGALDH1A1NPSR1MAOA | |
| SCHEMBL1072830 | 0.79 | PPARG (0.62) | MAPTPPARGALDH1A1NPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| CN-1455769-A | Cyclic amine sulfonamides as beta-3 adrenergic receptor agonists | WYETH LTD (US) | 2003-11-12 | — | — | CN | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5330998-A | Anticholesterol agents | PFIZER INC. (US) | 1994-07-19 | — | — | US | disclosed |
| EP-0389699-B1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER (US) | 1994-05-11 | — | — | EP | disclosed |
| EP-0332331-B1 | Thiazolidinedione hypoglycemic agents | PFIZER (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5223522-A | Anticholesterol agents | PFIZER INC. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5120754-A | Anticholesterol and antidiabetic agents | PFIZER INC. (US) | 1992-06-09 | — | — | US | disclosed |
| US-5061717-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1991-10-29 | — | — | US | disclosed |
| EP-0389699-A1 | Thiazolidinedione derivatives as hypoglycemic agents | PFIZER INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| WO-1989008652-A1 | THIAZOLIDINEDIONE DERIVATIVES AS HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885PPARG 787/4885ALDH1A1 1091/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | MAPT 4279/4885PPARG 1187/4885ALDH1A1 2651/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885PPARG 787/4885ALDH1A1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.